Post by ICON plc

First in human development of oligonucleotide drugs requires careful safety evaluation as molecular complexity increases. In this webinar, ICON specialists discuss best practices for FIH ON study design and risk mitigation, sharing practical insights into PK/PD, toxicity, dose escalation, immunogenicity, and QT assessment. Register now: https://ow.ly/lI2650YMC4V #Oligonucleotides #FIH